[Form 4] Idexx Laboratories Inc Insider Trading Activity
Michael Lane, Executive Vice President of Idexx Laboratories (IDXX), reported multiple stock and option transactions dated 08/06/2025. The filing shows acquisitions of 1,286 and 7,125 shares (prices listed as $206.94 and $288.78), and dispositions of 5,631, 2,480 and 300 shares at weighted-average prices of $627.5634, $627.9911 and $628.8866, respectively. After these transactions the filing reports total direct beneficial ownership of 7,131.9435 shares and an additional 592 shares held indirectly by the reporting person鈥檚 spouse in an IRA.
The filing also lists non-qualified stock option awards related to the reporting person: a right associated with 1,286 underlying shares (exercise price $206.94) and a right associated with 7,125 underlying shares (exercise price $288.78). Explanations note prior grants exercisable in installments beginning in 2020 and 2021 and purchases of 28.7090 shares under the issuer鈥檚 Employee Stock Purchase Plan.
Michael Lane, Vicepresidente esecutivo di Idexx Laboratories (IDXX), ha dichiarato pi霉 operazioni su azioni e opzioni datate 08/06/2025. La comunicazione riporta acquisizioni di 1,286 e 7,125 azioni (prezzi indicati $206.94 e $288.78) e dismissioni di 5,631, 2,480 e 300 azioni ai prezzi medi ponderati di $627.5634, $627.9911 e $628.8866, rispettivamente. Dopo queste operazioni la comunicazione segnala una propriet脿 diretta beneficiaria totale di 7,131.9435 azioni e un'ulteriore posizione di 592 azioni detenute indirettamente dal coniuge della persona segnalante in un IRA.
La segnalazione elenca inoltre premi in opzioni su azioni non qualificate relativi alla persona che effettua la dichiarazione: un diritto su 1,286 azioni sottostanti (prezzo di esercizio $206.94) e un diritto su 7,125 azioni sottostanti (prezzo di esercizio $288.78). Le note precisano concessioni precedenti esercitabili in tranche a partire dal 2020 e dal 2021 e acquisti per 28.7090 azioni nell'ambito del Piano di Acquisto Azionario per Dipendenti dell'emittente.
Michael Lane, vicepresidente ejecutivo de Idexx Laboratories (IDXX), inform贸 m煤ltiples transacciones de acciones y opciones con fecha 08/06/2025. El aviso muestra adquisiciones de 1,286 y 7,125 acciones (precios indicados $206.94 y $288.78), y enajenaciones de 5,631, 2,480 y 300 acciones a precios promedio ponderados de $627.5634, $627.9911 y $628.8866, respectivamente. Tras estas operaciones, el documento informa una propiedad beneficiaria directa total de 7,131.9435 acciones y 592 acciones adicionales mantenidas indirectamente por el c贸nyuge de la persona informante en una IRA.
El documento tambi茅n enumera adjudicaciones de opciones sobre acciones no calificadas relacionadas con la persona que informa: un derecho vinculado a 1,286 acciones subyacentes (precio de ejercicio $206.94) y un derecho vinculado a 7,125 acciones subyacentes (precio de ejercicio $288.78). Las aclaraciones se帽alan concesiones previas ejercitables en cuotas a partir de 2020 y 2021 y compras de 28.7090 acciones bajo el Plan de Compra de Acciones para Empleados del emisor.
Michael Lane鞚赌 Idexx Laboratories (IDXX)鞚� 攵�靷灔(Executive Vice President)鞙茧靹� 08/06/2025鞛� 鞐煬 欤检嫕 氚� 鞓奠厴 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 臧侁皝 $206.94鞕赌 $288.78搿� 1,286欤� 氚� 7,125欤茧ゼ 旆摑頃� 雮挫棴瓿�, 臧�欷戫弶攴� 臧�瓴� $627.5634, $627.9911, $628.8866搿� 臧侁皝 5,631欤�, 2,480欤�, 300欤茧ゼ 觳橂秳頃� 雮挫棴鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞚措煬頃� 瓯半灅 頉� 鞁犼碃靹滌棎電� 齑� 歆侅爲 鞁れ唽鞙犼秾鞚� 7,131.9435欤检澊氅�, 鞁犼碃鞛愳潣 氚办毎鞛愱皜 IRA鞐愳劀 臧勳爲鞝侅溂搿� 氤挫湢頃� 592欤缄皜 於旉皜搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 鞁犼碃鞛愳櫠� 甏�霠悳 牍勳爜瓴� 鞀ろ啞鞓奠厴 靾橃棳 雮挫棴鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟: 頄夓偓臧� $206.94鞚� 旮办磮欤检嫕 1,286欤检棎 雽�頃� 甓岆Μ鞕赌 頄夓偓臧� $288.78鞚� 旮办磮欤检嫕 7,125欤检棎 雽�頃� 甓岆Μ鞛呺媹雼�. 靹る獏鞐愲姅 2020雲� 氚� 2021雲勲秬韯� 攵勴暊搿� 頄夓偓 臧�電ロ暅 鞚挫爠 攵�鞐櫠� 氚滍枆靷潣 膦呾梾鞗� 欤检嫕 毵れ瀰 瓿勴殟(ESPP)鞚� 韱淀暣 旆摑頃� 28.7090欤� 甑Г 雮挫棴鞚� 鞏戈笁霅橃柎 鞛堨姷雼堧嫟.
Michael Lane, vice鈥憄r茅sident ex茅cutif de Idexx Laboratories (IDXX), a d茅clar茅 plusieurs op茅rations sur actions et options dat茅es du 08/06/2025. Le dossier indique des acquisitions de 1,286 et 7,125 actions (prix indiqu茅s $206.94 et $288.78) et des cessions de 5,631, 2,480 et 300 actions 脿 des prix moyens pond茅r茅s de $627.5634, $627.9911 et $628.8866, respectivement. Apr猫s ces op茅rations, le dossier fait 茅tat d'une d茅tention directe b茅n茅ficiaire totale de 7,131.9435 actions et de 592 actions suppl茅mentaires d茅tenues indirectement par le conjoint de la personne d茅clarante dans un IRA.
Le dossier mentionne 茅galement des attributions d'options sur actions non qualifi茅es concernant la personne d茅clarante : un droit portant sur 1,286 actions sous鈥慾acentes (prix d'exercice $206.94) et un droit portant sur 7,125 actions sous鈥慾acentes (prix d'exercice $288.78). Les explications indiquent des attributions ant茅rieures exer莽ables par tranches 脿 compter de 2020 et 2021 ainsi que des achats de 28.7090 actions dans le cadre du Plan d'Achat d'Actions pour les Employ茅s de l'茅metteur.
Michael Lane, Executive Vice President von Idexx Laboratories (IDXX), meldete mehrere Aktien- und Optionsgesch盲fte datiert 08/06/2025. Die Einreichung weist Erwerbe von 1,286 und 7,125 Aktien (angegebene Preise $206.94 bzw. $288.78) sowie Ver盲u脽erungen von 5,631, 2,480 und 300 Aktien zu gewichteten Durchschnittspreisen von $627.5634, $627.9911 und $628.8866 aus. Nach diesen Transaktionen gibt die Meldung einen gesamten direkten wirtschaftlichen Besitz von 7,131.9435 Aktien an sowie zus盲tzlich 592 Aktien, die indirekt durch die Ehefrau der meldenden Person in einem IRA gehalten werden.
Die Meldung listet au脽erdem nicht qualifizierte Aktienoptionszuteilungen im Zusammenhang mit der meldenden Person: ein Recht auf 1,286 zugrunde liegende Aktien (Aus眉bungspreis $206.94) und ein Recht auf 7,125 zugrunde liegende Aktien (Aus眉bungspreis $288.78). Erl盲uterungen verweisen auf fr眉here Zuteilungen, die in Raten ab 2020 bzw. 2021 aus眉bbar sind, sowie auf K盲ufe von 28.7090 Aktien im Rahmen des Employee Stock Purchase Plan des Emittenten.
- Acquisitions of 8,411 shares reported (1,286 at $206.94 and 7,125 at $288.78), demonstrating additional insider stock exposure.
- Non-qualified stock option awards are disclosed for 1,286 and 7,125 underlying shares with stated exercise prices, providing clarity on potential future share issuance.
- Employee Stock Purchase Plan purchases of 28.7090 shares are explicitly disclosed in the explanations.
- Dispositions of 8,411 shares reported across multiple sales at high weighted-average prices (~$627.56 to $628.89), reducing direct holdings to 7,131.9435 shares.
- Significant transaction volume (total shares bought and sold equal 8,411) may be viewed by some investors as notable insider trading activity given the large absolute share counts.
Insights
TL;DR: Insider reported matched purchases and sales totaling 8,411 shares, leaving ~7,132 shares directly owned.
The reported activity is detailed and sizeable in share count: acquisitions of 8,411 shares at substantially lower per-share prices and dispositions of 8,411 shares at approximately $627鈥�$629 per share, resulting in reported direct beneficial ownership of 7,131.9435 shares and 592 shares held indirectly by the spouse. The filing also confirms existing non-qualified stock option awards tied to 1,286 and 7,125 underlying shares with documented exercise prices.
TL;DR: Routine executive stock and option reporting; transactions are material in size but appear to be documented transparently.
The Form 4 provides clear line-item disclosure of acquisitions, sales and option holdings for an Executive Vice President and Director. The presence of option grants exercisable in installments and ESPP purchases is explicitly disclosed. From a governance and disclosure perspective, the form meets Section 16 transparency requirements by reporting quantities, prices and ownership form, enabling investors to see the changes in beneficial ownership.
Michael Lane, Vicepresidente esecutivo di Idexx Laboratories (IDXX), ha dichiarato pi霉 operazioni su azioni e opzioni datate 08/06/2025. La comunicazione riporta acquisizioni di 1,286 e 7,125 azioni (prezzi indicati $206.94 e $288.78) e dismissioni di 5,631, 2,480 e 300 azioni ai prezzi medi ponderati di $627.5634, $627.9911 e $628.8866, rispettivamente. Dopo queste operazioni la comunicazione segnala una propriet脿 diretta beneficiaria totale di 7,131.9435 azioni e un'ulteriore posizione di 592 azioni detenute indirettamente dal coniuge della persona segnalante in un IRA.
La segnalazione elenca inoltre premi in opzioni su azioni non qualificate relativi alla persona che effettua la dichiarazione: un diritto su 1,286 azioni sottostanti (prezzo di esercizio $206.94) e un diritto su 7,125 azioni sottostanti (prezzo di esercizio $288.78). Le note precisano concessioni precedenti esercitabili in tranche a partire dal 2020 e dal 2021 e acquisti per 28.7090 azioni nell'ambito del Piano di Acquisto Azionario per Dipendenti dell'emittente.
Michael Lane, vicepresidente ejecutivo de Idexx Laboratories (IDXX), inform贸 m煤ltiples transacciones de acciones y opciones con fecha 08/06/2025. El aviso muestra adquisiciones de 1,286 y 7,125 acciones (precios indicados $206.94 y $288.78), y enajenaciones de 5,631, 2,480 y 300 acciones a precios promedio ponderados de $627.5634, $627.9911 y $628.8866, respectivamente. Tras estas operaciones, el documento informa una propiedad beneficiaria directa total de 7,131.9435 acciones y 592 acciones adicionales mantenidas indirectamente por el c贸nyuge de la persona informante en una IRA.
El documento tambi茅n enumera adjudicaciones de opciones sobre acciones no calificadas relacionadas con la persona que informa: un derecho vinculado a 1,286 acciones subyacentes (precio de ejercicio $206.94) y un derecho vinculado a 7,125 acciones subyacentes (precio de ejercicio $288.78). Las aclaraciones se帽alan concesiones previas ejercitables en cuotas a partir de 2020 y 2021 y compras de 28.7090 acciones bajo el Plan de Compra de Acciones para Empleados del emisor.
Michael Lane鞚赌 Idexx Laboratories (IDXX)鞚� 攵�靷灔(Executive Vice President)鞙茧靹� 08/06/2025鞛� 鞐煬 欤检嫕 氚� 鞓奠厴 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 臧侁皝 $206.94鞕赌 $288.78搿� 1,286欤� 氚� 7,125欤茧ゼ 旆摑頃� 雮挫棴瓿�, 臧�欷戫弶攴� 臧�瓴� $627.5634, $627.9911, $628.8866搿� 臧侁皝 5,631欤�, 2,480欤�, 300欤茧ゼ 觳橂秳頃� 雮挫棴鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞚措煬頃� 瓯半灅 頉� 鞁犼碃靹滌棎電� 齑� 歆侅爲 鞁れ唽鞙犼秾鞚� 7,131.9435欤检澊氅�, 鞁犼碃鞛愳潣 氚办毎鞛愱皜 IRA鞐愳劀 臧勳爲鞝侅溂搿� 氤挫湢頃� 592欤缄皜 於旉皜搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 鞁犼碃鞛愳櫠� 甏�霠悳 牍勳爜瓴� 鞀ろ啞鞓奠厴 靾橃棳 雮挫棴鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟: 頄夓偓臧� $206.94鞚� 旮办磮欤检嫕 1,286欤检棎 雽�頃� 甓岆Μ鞕赌 頄夓偓臧� $288.78鞚� 旮办磮欤检嫕 7,125欤检棎 雽�頃� 甓岆Μ鞛呺媹雼�. 靹る獏鞐愲姅 2020雲� 氚� 2021雲勲秬韯� 攵勴暊搿� 頄夓偓 臧�電ロ暅 鞚挫爠 攵�鞐櫠� 氚滍枆靷潣 膦呾梾鞗� 欤检嫕 毵れ瀰 瓿勴殟(ESPP)鞚� 韱淀暣 旆摑頃� 28.7090欤� 甑Г 雮挫棴鞚� 鞏戈笁霅橃柎 鞛堨姷雼堧嫟.
Michael Lane, vice鈥憄r茅sident ex茅cutif de Idexx Laboratories (IDXX), a d茅clar茅 plusieurs op茅rations sur actions et options dat茅es du 08/06/2025. Le dossier indique des acquisitions de 1,286 et 7,125 actions (prix indiqu茅s $206.94 et $288.78) et des cessions de 5,631, 2,480 et 300 actions 脿 des prix moyens pond茅r茅s de $627.5634, $627.9911 et $628.8866, respectivement. Apr猫s ces op茅rations, le dossier fait 茅tat d'une d茅tention directe b茅n茅ficiaire totale de 7,131.9435 actions et de 592 actions suppl茅mentaires d茅tenues indirectement par le conjoint de la personne d茅clarante dans un IRA.
Le dossier mentionne 茅galement des attributions d'options sur actions non qualifi茅es concernant la personne d茅clarante : un droit portant sur 1,286 actions sous鈥慾acentes (prix d'exercice $206.94) et un droit portant sur 7,125 actions sous鈥慾acentes (prix d'exercice $288.78). Les explications indiquent des attributions ant茅rieures exer莽ables par tranches 脿 compter de 2020 et 2021 ainsi que des achats de 28.7090 actions dans le cadre du Plan d'Achat d'Actions pour les Employ茅s de l'茅metteur.
Michael Lane, Executive Vice President von Idexx Laboratories (IDXX), meldete mehrere Aktien- und Optionsgesch盲fte datiert 08/06/2025. Die Einreichung weist Erwerbe von 1,286 und 7,125 Aktien (angegebene Preise $206.94 bzw. $288.78) sowie Ver盲u脽erungen von 5,631, 2,480 und 300 Aktien zu gewichteten Durchschnittspreisen von $627.5634, $627.9911 und $628.8866 aus. Nach diesen Transaktionen gibt die Meldung einen gesamten direkten wirtschaftlichen Besitz von 7,131.9435 Aktien an sowie zus盲tzlich 592 Aktien, die indirekt durch die Ehefrau der meldenden Person in einem IRA gehalten werden.
Die Meldung listet au脽erdem nicht qualifizierte Aktienoptionszuteilungen im Zusammenhang mit der meldenden Person: ein Recht auf 1,286 zugrunde liegende Aktien (Aus眉bungspreis $206.94) und ein Recht auf 7,125 zugrunde liegende Aktien (Aus眉bungspreis $288.78). Erl盲uterungen verweisen auf fr眉here Zuteilungen, die in Raten ab 2020 bzw. 2021 aus眉bbar sind, sowie auf K盲ufe von 28.7090 Aktien im Rahmen des Employee Stock Purchase Plan des Emittenten.
FAQ
What transactions did Michael Lane report on the IDXX Form 4?
How many IDXX shares does Michael Lane beneficially own after these transactions?
At what prices were the shares sold according to the filing?
What option awards are disclosed for Michael Lane on this Form 4?
Are there any indirect holdings reported in the Form 4?
